Michael A. Mussallem - 13 Jan 2023 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
Chairman & CEO, Director
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
13 Jan 2023
Net transactions value
-$518,221
Form type
4
Filing time
13 Jan 2023, 17:41:05 UTC
Previous filing
14 Dec 2022
Next filing
14 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $1,033,903 +29,375 +19% $35.20 186,728 13 Jan 2023 Direct F1
transaction EW Common Stock Gift $0 -9,500 -5.1% $0.000000 177,228 13 Jan 2023 Direct
transaction EW Common Stock Sale $1,552,124 -19,875 -11% $78.09 157,353 13 Jan 2023 Direct F1, F2
transaction EW Common Stock Gift $0 +9,500 +0.27% $0.000000 3,482,517 13 Jan 2023 By Living Trust
holding EW Common Stock 371,705 13 Jan 2023 401(k)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -29,375 -20% $0.000000 117,500 13 Jan 2023 Common Stock 29,375 $35.20 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2022.
F2 This transaction was executed in multiple trades at prices ranging from $77.43 to $78.40 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.